ArticleCell metabolism2020
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.
Article in Cell metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Associations between changes in the gut microbiota and liver cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Influence of Alcohol on the Intestinal Immune System.Alcohol research : current reviews · 2025Pooled it
- The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.Hepatology (Baltimore, Md.) · 2021Trial
- Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosis.Cellular and molecular life sciences : CMLS · 2026Review
- Gut microbiota and host transcriptome interactions reveal diagnostic biomarkers in MASLD-associated hepatocellular carcinoma.Gut pathogens · 2025Article
- Review
- Credible inferences in microbiome research: ensuring rigour, reproducibility and relevance in the era of AI.Nature reviews. Gastroenterology & hepatology · 2025Review
- Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review.Journal of advanced research · 2025Review
- Gut microbiota involvement in the effect of water-soluble dietary fiber on fatty liver and fibrosis.Bioscience of microbiota, food and health · 2025Article
- Microbiota composition and intestinal barrier function modulated by tamsulosin andFrontiers in cellular and infection microbiology · 2025Article
- Article
- Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD.Nutrients · 2024Article
- The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2023Review
- Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.Life metabolism · 2023Review
- The human microbiome and gut-liver axis in people living with HIV.Current HIV/AIDS reports · 2023Review
- Article
- Artificial intelligence models for the diagnosis and management of liver diseases.Ultrasonography (Seoul, Korea) · 2023Article
- Are Ingested or Inhaled Microplastics Involved in Nonalcoholic Fatty Liver Disease?International journal of environmental research and public health · 2022Review
- A machine learning framework for discovery and enrichment of metagenomics metadata from open access publications.GigaScience · 2022Article
- AI/ML-driven advances in untargeted metabolomics and exposomics for biomedical applications.Cell reports. Physical science · 2022Article
Corrections and comments
- Erratum for
Authors and funding
18 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.